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Preamble
The granting of staff privileges to physicians is an important
mechanism to ensure quality care. The Joint Commission
on Accreditation of Healthcare Organizations requires that
medical staff privileges be based on professional criteria
specified in medical staff bylaws. Physicians are charged
with defining the criteria that constitute professional com-
petence and with evaluating their peers accordingly. With
the evolution of transcatheter aortic valve replacement
(TAVR), an important opportunity arises for both cardiol-
ogists and surgeons to come together to identify the criteria
for performing these procedures. The Society for Cardio-
vascular Angiography and Interventions (SCAI), American
Association for Thoracic Surgery (AATS), American Col-
lege of Cardiology Foundation (ACCF), and The Society of
Thoracic Surgeons (STS) have, therefore, joined together to
provide recommendations for institutions to assess their
potential for instituting and/or maintaining a transcatheter
valve program. This article concerns TAVR. As TAVR is in
its infancy, there are few data on which to base this
consensus statement. Therefore, many of these recommen-
dations are based on expert consensus. As the procedures
evolve, technology changes, experience grows, and more
data is accumulated, there will certainly be a need to update
this consensus statement. However, with the Food and
Drug Administration (FDA) having just approved the first
generation of TAVR devices, the writing committee and
participating societies believe that the recommendations
listed in this report serve as an appropriate starting point. In
some ways, these recommendations apply to institutions
more than to individuals. As there is a strong consensus that
these new valve therapies are best performed using a team
approach, these credentialing criteria may be best applied
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ACCF’s policy on relationships with industry and other
entities (RWI) to author this document (http://
www.cardiosource.org/Science-And-Quality/Practice-
Guidelines-and-Quality-Standards/Relationships-With-
Industry-Policy.aspx). To avoid actual, potential, or
perceived conflicts of interest that may arise as a result of
industry relationships or personal interests among the
writing committee, all members of the writing commit-
tee, as well as peer reviewers of the document, were asked
to disclose all current healthcare-related relationships,
including those existing 12 months before initiation of
the writing effort. A committee of interventional cardi-
ologists and surgeons was formed to include a majority of
members with no relevant RWI and be led by an
interventional cardiology co-chair and a surgical co-chair
with no relevant RWI. Authors with relevant RWI were
not permitted to draft or vote on text or recommenda-
tions pertaining to their RWI. RWI were reviewed on all
conference calls and updated as changes occurred. Author
and peer reviewer RWI pertinent to this document are
disclosed in Appendices 1 and 2, respectively. In addi-
tion, to ensure complete transparency, authors’ compre-
hensive disclosure information (including RWI not per-
tinent to this document) is available as an online
supplement to this document. The work of the writing
committee was supported exclusively by the partnering
societies without commercial support. Writing commit-
tee members volunteered their time to this effort. Con-
ference calls of the writing committee were confidential
and attended only by committee members. SCAI, AATS,
ACCF, and STS believe that adherence to these recom-
mendations will maximize the chances that these thera-
pies will become a successful part of the armamentarium
for treating valvular heart disease in the United States. In
addition, these recommendations will hopefully facilitate
optimum quality during the delivery of this therapy,
which will be important to the development and success-
ful implementation of future, less invasive approaches to
structural heart disease.
Introduction
Enabled by the development of new technologies, treatment
of valvular heart disease by transcatheter techniques is
becoming a favored approach of cardiac providers, resulting
in less invasive treatment for patients previously treatable
only with open heart surgery or, in many cases, not treatable
at all. Recognition from the medical community of the
applicability, effectiveness, and practicality of catheter-based
transcatheter valve therapies has further increased interest in
these treatments. Training program content, standards,
credentialing, and board certifications for cardiac surgical
procedures and percutaneous coronary intervention (PCI)
are well developed, but no such structure exists in the fieldof percutaneous structural or valvular heart disease thera-
pies. The purpose of this article is to outline criteria for
operator and institutional requirements to enable institu-
tions and providers to participate responsibly in this new
and rapidly developing field.
The emergence of transcatheter aortic valve repair and
implantation as an alternative to traditional surgical therapy
for valvular diseases has been facilitated by innovative
devices, rapidly developing techniques, and careful patient
selection (1). The combination of interventional skills,
equipment, collaborative clinical management, surgical ap-
proaches, techniques, and decision-making distinguish the
qualifications to participate in this field as unique, as does
the complexity of the patients requiring these therapies
(1–3). Given both the high-risk nature of these catheter
interventions and the availability of established alternative
treatment options using traditional surgical approaches,
several considerations are important for institutions and
operators planning to implement these new technologies.
Defining operator and institutional requirements for
these novel therapies is an important first step in ensuring
their optimal implementation.
Establishing a structural heart disease intervention therapy
program requires several key components (Tables 1 and 2).
he defining principle is that this effort is a joint,
nstitutionally-based activity for cardiologists and cardiac
urgeons (1,4). Thus, the specialty that provides some of
hese components will vary from program to program. A
ranscatheter aortic valve replacement (TAVR) program
hat uses only one specialty is fundamentally deficient, and
alve therapy programs should not be established without
his multidisciplinary partnership. Comprehensive multidis-
iplinary teams (MDTs) are, therefore, required for trans-
atheter valve therapies.
Knowledge Base and Skills
The critical cornerstone for establishing a transcatheter
valve program is the formal collaborative effort between
interventional cardiologists and cardiac surgeons. This ele-
ment is essential for establishing a transcatheter valve
program. No one individual, group, or specialty possesses all
the necessary skills for best patient outcomes (1,5). The
over-arching goal of these programs must be to provide the
best possible patient-centered care (1,6).
As these are new techniques, the correlation between
operator experience and performance metrics for these
procedures has yet to be established. The current pool of
trained individuals is comprised predominantly of those
who have participated in industry-sponsored trials aimed at
device approval. Therefore, the translation of currently
available experiences with transcatheter valve therapies to
the “real world” has yet to be evaluated in the United States.
Several core concepts should be implemented for all physi-
cians performing these procedures, irrespective of their spe-
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knowledge of valvular heart disease, including the natural
history of the disease, hemodynamics, appropriate diagnostics,
optimal medical therapy, application and outcome of invasive
therapies, and procedural and perioperative care (9).
The ability to interpret echocardiographic and other
radiographic images (obtained at baseline, during the pro-
cedure, and follow-up) is critically important. MDTs and
procedural teams need to possess echocardiographic interpre-
tation skills for transthoracic and transesophageal studies. The
use of three-dimensional (3D) and four-dimensional echoes
may evolve to become essential diagnostic tools. Expertise in
the interpretation of computed tomography (CT) scans of the
Table 1. Transcatheter Aortic Valve Replacement: Criteria for N
New Programs
Institutional Interventional Program 1,000 cath/400 PCI per
TAVR Interventionalist 100 Structural procedure
valvuloplasty (Left side
and mitral valve (MV) p
defect/patent foramen
Suitable training on devic
Institutional Surgical Program 50 Total AVR per year of
Minimum of 2 instituti
surgical program)
TAVR Surgeon 100 AVR career, at least
and at least 20 AVR in
Experience with, and ma
Experience with open ret
Suitable training on devic
Training Cardiologists must be bo
Surgeons must be board
Additional operators wh
hospital privileges in
the interventional car
Existing Programs
Institutional Programs in existence 
Programs in existence 
Training Cardiologists must be bo
Surgeons must be board
Additional operators wh
hospital privileges in
the interventional car
aWith acceptable outcomes for conventional procedures compared to NCDR benchmarks.
Table 2. Volume and Outcomes for Continued Certification for
Both New and Existing TAVR Programs Applies to
“Inoperable’’ (PARTNER Cohort B) TAVR Patients
Program volume of 20 TAVR per year or 40 per 2 years
30 day all-cause mortality 15%
30 day all-cause neurologic events including transient ischemic attack
(TIAs) 15%
Major vascular complication 15%a
90% Institutional follow-up
60% 1-year survival rate for nonoperable patients (cohort b)—after the
program has been running for 2 years (2-year average)
Ongoing continuing medical education (CME) (or nursing/technologist
equivalent) of 10 hr per year of relevant material
All cases must be submitted to a single national databaseaAccording to VARC-2 (Valve Academic Research Consortium) (9a) definitions.iliofemoral vessels, cardiac anatomy, as well as aortic valvular
anatomy, is critical for determining patient eligibility and the
approach for procedures (8,10).
As noted, there is as yet no demonstrated direct correla-
tion between operator experience with specific procedures
and the skills necessary to perform transcatheter valve
procedures, although there are some procedures that require
similar prerequisite skills such as balloon aortic valvuloplasty
(BAV) for TAVR. There are, however, some core concepts
that professional societies have accepted as important for
both facilities and operators (1,11,12). Minimum training
for specific procedures and devices will, for the immediate
future, be primarily dictated by FDA approval require-
ments. Simulation is likely to play a significant role in
technical training and proficiency maintenance for these
evolving procedures (13–17). As these procedures become
integrated into mainstream care delivery, the strategy for
training will likely need to be revised.
Minimum requirements for transcatheter valve therapies
include an understanding of basic radiation safety necessary
for optimal imaging, operator and patient exposure protec-
tion, and knowledge of the use of X-ray contrast agents,
which may not be standard in cardiac surgery training and
experience.
Training in the use of closed systems for hemodynamic
monitoring and contrast injections will result in optimal
integration into catheterization laboratories and hybrid
and Existing Programs
ime or 30 left sided structural per year of which 60% should be balloon aortic
edures include EVAR, TEVAR, BALLOON AORTIC VALVE (BAV), aortic valve (AV)
etic leak closures and ventricular septal defect [VSD] closures). (atrial septal
(ASD/PFO) closure are not considered left sided procedures)
be used
at least 10 aortic valve replacement (AVR) should be high-risk (STS score 6)
-based cardiac surgeons in program (more than 50% time at hospital with
which are “high-risk” (STS score 6) or 25 AVR per year or 50 AVR in 2 years
ear prior to TAVR initiation
ent of, peripherally inserted cardiopulmonary bypass
toneal exposure of, and surgical intervention on, the iliac arteries
be used
rtified/eligible in interventional cardiology
ed/eligible in thoracic surgery
trained or experienced in structural heart disease, and have unrestricted
ural procedures, may also be part of the interventional operating team with
ist and cardiovascular surgeon
nths: 30 TAVR (total experience)
nths: 2 per month
rtified/eligible in interventional cardiology
ed/eligible in thoracic surgery
trained or experienced in structural heart disease, and have unrestricted
ural procedures, may also be part of the interventional operating team with
ist and cardiovascular surgeonew
yeara
s lifet
d proc
rosth
ovale
es to
which
onally
10 of
last y
nagem
roperi
es to
ard ce
certifi
o are
struct
diolog
18 mo
18 mo
ard ce
certifi
o are
struct
diologenvironments. Catheter and wire skills, including knowl-
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available to access complex anatomy and negotiating neces-
sary vascular and anatomic structures are required. Under-
standing of the interplay of wires, catheters, and anatomy is
required for completion of these procedures. These skills
can be acquired in a variety of ways. Prior experience with a
variety of interventional techniques is important. These
include but are not limited to:
• Coronary diagnostic procedures
• Coronary interventions
• Peripheral vascular diagnostic procedures
• Peripheral vascular interventions
• Balloon aortic, mitral, and pulmonic valve dilatation
• Stent implantation in right ventricle outflow tract and
pulmonary arteries
• Intra-aortic balloon pump (IABP), other cardiac sup-
port device placement, including initiation of percuta-
neous cardiopulmonary bypass
• Percutaneous ventricular assist device placement
• Endovascular aneurysm repair (EVAR) or thoracic
endovascular aortic repair (TEVAR) procedures
• Transseptal techniques
• Coronary sinus access
• Large vessel access and closure
Operators should also have experience with specific
catheter-based techniques required for valve interventions.
Similarly, surgeons should have experience with transapical
approaches for left ventricular assist device placement and
care of similar high-risk patients to perform transapical
TAVR (11,12,18). The experience of an interventionalist or
surgeon should be relevant to the transcatheter valve pro-
cedure undertaken. In this document, attention will focus
on cardiac surgery and interventional cardiology experience
relevant to aortic valve intervention.
The concept of sterile technique must be completely
understood and stringently applied to the delivery of trans-
catheter valve therapies. Interventionalists must understand
and be able to function in an environment that has more
stringent sterile technique requirements than are common
in catheterization laboratories. As one of the leaders of the
team performing these procedures, the interventionalist
must be able to enforce compliance with these standards.
These procedures may involve open or partially open surgi-
cal components. Also, large devices that possess the same
risk of infection as conventional valve prostheses will be
implanted, especially for valve replacement procedures. Op-
erating theater standards for sterile technique are, therefore,
mandatory to ensure best patient outcomes.
Facilities
The institution should have an active valvular heart disease
surgical program with at least two institutionally-based
cardiac surgeons experienced in valvular surgery, and shouldcontain a full range of diagnostic imaging and therapeutic
facilities including:
1. Cardiac catheterization laboratory or hybrid operating
room (OR)/cath lab equipped with a fixed radiographic
imaging system with flat-panel fluoroscopy, offering
catheterization laboratory quality imaging. A biplane
unit may be advantageous, particularly for congenital
heart disease.
2. Noninvasive imaging
a. Echocardiographic laboratory. Transthoracic and
transesophageal echocardiographic capabilities with
sonographers and echocardiographers experienced in
valvular heart disease. Access to 3D echocardiography
is preferable.
b. Vascular laboratory (noninvasive) with vascular spe-
cialists capable of performing and interpreting vascu-
lar studies.
c. CT laboratory with CT technologists and specialists
who can acquire and interpret cardiac CT studies.
3. Physical space—The implantation suite must have a
sterile environment that meets OR standards. Further-
more, it must have sufficient space to accommodate the
necessary equipment for uncomplicated implantations as
well as any additional equipment that may be necessary
in the event of complications. This includes space for
anesthesiology, echocardiography, and cardiopulmonary
bypass equipment and personnel. A specifically designed
hybrid OR interventional suite is ideal; however, in the
absence of such a facility, the interventional cardiac suite
should have:
a. Circulating heating, ventilation, and air conditioning
laminar flow diffusers (providing smooth, undisturbed
air flow and usually placed directly over the procedure
table) to meet air requirements for surgery rooms.
b. Asymmetrical/symmetrical six-lamp 2  4 troffers
(the inverted, usually metal trough suspended from
the ceiling as a fixture for fluorescent lighting) to
provide adequate high-output lighting for surgical
intervention.
c. Adequate number of power receptacles that meet
surgical equipment requirements.
d. Capability of running cardiopulmonary bypass appa-
ratus in the interventional suite.
e. Gas outlets for the anesthesia machine.
f. Adequate room size to accommodate the standard
equipment required in a cardiac catheterization labo-
ratory (e.g., high-definition displays and monitors, O2
analyzer, defibrillator/resuscitation cart, O2 supply,
suction, compressed air, CO-oximeter, activated clot-
ting time analyzer).
g. Minimum room size of 800 square feet (74.3 m2) to
accommodate echocardiographic equipment, sonog-
raphers, anesthesia equipment, emergency CT surgi-
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surgeon, assistant, scrub tech, pump techs), if needed.
4. Fungible equipment—The interventional suite should
stock a large variety of fungible equipment, including
various access kits, endovascular sheath and introducers
ranging from 4 to 26 F in various lengths, a wide range
of guide wires for various purposes, cardiac diagnostic
and interventional catheters, vascular closure devices,
balloon dilatation catheters ranging from 2 to 30 mm in
diameter and of various lengths and profiles, bare metal
and covered stents (e.g., coronary and peripheral), occlu-
sive vascular devices, snares and other retrieval devices,
drainage catheters, and various implantable device sizes
with their delivery systems.
5. Postprocedure intensive care facility with personnel ex-
perienced in managing patients who have undergone
conventional open heart valve procedures.
6. Use of mobile C-arm imaging system in an OR is not
adequate.
7. HYBRID OR—The “2012 American College of Car-
diology Foundation/Society for Cardiovascular Angiog-
raphy and Interventions Expert Consensus Document
on Cardiac Catheterization Laboratory Standards Up-
date” will outline the specifications for a hybrid Cath
Lab/OR (18a). Though this is preferable, it is not a
prerequisite since it is not available at many institutions.
Most importantly, there must be dedication on the part of
the hospital to provide these services and support, both
financially and with no time constraints on the personnel
involved. A dedicated administrator as a member of the
team is necessary.
Other Institutional Resources
For preprocedure and postprocedure care and joint formal
multidisciplinary patient consultation, adequate outpatient
clinical care facilities are necessary. Appropriate office space
for the medical, nursing, and technical personnel involved is
also required, preferably in a central setting. Ancillary
testing facilities (i.e., pulmonary function, echocardiogra-
phy, vascular Duplex scanning, clinical laboratory, multislice
CT) should be of high quality and able to accommodate the
patient load on a timely basis.
By their very nature, these complex procedures should
only be performed in institutions that currently and rou-
tinely perform large volumes of surgical aortic valve opera-
tions with outcomes that equal or exceed those established
nationally for similar procedures. Similarly, only institutions
with interventional cardiology programs that have estab-
lished and successful programs with BAV, catheter closure
of periprosthetic valvular leaks, insertion of ventricular
septal closure devices with outcomes that equal or exceed
those established nationally for similar procedures should
develop an integrated structural heart MDT.The institutional commitment required for a successful
program goes beyond the necessary space, personnel, and
specialized facilities set forth above. The complex and time
consuming preprocedure patient triage process and the
amount and intensity of postprocedure patient care after
discharge are very labor intensive for the physician and
nursing staff, as are the informed consents and communi-
cations with patients, families, and referring providers. In
addition to supporting the core nursing and technical
support staff, arrangements between the institution and the
physicians need to be structured to reimburse physician
efforts dedicated to nonreimbursable hours of clinical care
and medical management of the program.
The complexity of transcatheter valve procedures and the
magnitude of institutional resources required are similar to
established heart transplant and cardiac assist device pro-
grams, where dedicated professionals, a minimum of infra-
structure, MDT, registered nurse/nurse practitioner (NP),
providers, coordinators, databases, and quality reporting are
essential for optimal patient outcomes (1). This concept was
endorsed by the Centers for Medicare and Medicaid Ser-
vices (CMS) through the establishment of certification
criteria for the use of heart transplantation and cardiac assist
devices in centers and, moreover, for eligibility for reim-
bursement of services provided. The same regulatory system
was applied to professionals providing these services. Trans-
catheter valve treatment programs should undergo a similar
regulatory process with CMS endorsement. Centers should
be approved for transcatheter aortic valve programs based on
a minimum number of cases per year, and perioperative and
1-year outcomes above a minimum threshold.
Long-term outcome reporting is obligatory, to track not
only survival, but also other parameters including peripro-
cedural complications (CVA, vascular, renal, infectious,
etc.), aortic regurgitation, the need for reintervention, sub-
sequent surgery, and quality of life. This type of reporting is
essential, since long-term outcome goals for these new
procedures have not been established at this early stage.
Participation in a national data registry (e.g., STS/ACC
TVT Registry) is mandatory (1).
Multi-Disciplinary Team
The use of a team approach has been shown to improve
outcomes in these types of complex procedures (19). The
MDT necessary for a TAVR program is highlighted by the
collaboration between the interventional cardiologist and
cardiac surgeon (1). The MDT, however, goes well beyond
this collaboration, and must include key providers from
other physician groups (e.g., anesthesiology, radiology, non-
invasive cardiology, intensive care). In addition to the
individual physicians, other components that extend to
various departments are necessary. The idea that the MDT
is comprised of individual physicians working in a room
performing the procedures is a superficial view that does not
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successful valve therapy program. The interaction among
specialists in the MDT is fundamental, particularly for
preprocedure patient evaluation and selection. It is equally
fundamental that the patient be at the very center of all
discussions and decision-making regarding the best ther-
apy in her/his particular circumstance. While there is
great excitement about the application of transcatheter
valve therapies, most of these therapies will only be
indicated for a small portion of the population for the
immediate future. Proper decision-making and determi-
nation of best options for any given patient require an
evaluation by the MDT (20).
On-site valve surgery is an essential component of any
valve therapy program. The requirement for on-site valve
surgery is based not only on the potential need for emer-
gency or “back-up” surgery for percutaneous patients but
more importantly on the quality of patient evaluation and
selection, decision-making, intraprocedure management,
and postprocedure care and outcomes.
A cardiac surgeon and an interventional cardiologist must
evaluate every case. Interplay between interventional cardi-
ologists and cardiac surgeons represent only part of the
benefit of the MDT (1). As noted above, additional critical
contributions are provided by cardiac anesthesiologists, by
imaging specialists in both cardiology and radiology, and by
the many people who extend beyond the physician members
of the team. The MDT is led by a core of physicians from
interventional cardiology, cardiac surgery, cardiac anesthe-
siology, and intensive care and cardiac imaging depart-
ments, along with congenital heart disease specialists and
surgeons, in some instances. Depending on the institutional
organization and the needs of the patient, vascular surgery
and interventional radiology departments may also partici-
pate in the MDT. Additional team members include NPs
from all of these fields, research coordinators, and a dedi-
cated administrator.
The function of the MDT is essential in preprocedure
patient selection, intraprocedure management and problem
solving, postprocedure management, postdischarge follow-
up, and outcome studies. During procedures, emergencies
or unanticipated needs may arise as a matter of course even
in the most straightforward situation. The immediate avail-
ability of MDT support to help with decision-making or
with therapy is essential. A clear definition of roles for
different specialties as well as effective communication,
which may be different from that of conventional proce-
dures, is critical for successful outcomes. Difficult postpro-
cedure courses are common in the high-risk patients who
comprise a large part of the target population for both
transcatheter and operative valve therapies. A team ap-
proach to problem solving in this setting is critical. Another
important part of patient management is the familiarity that
the intensive care unit and the monitored step-down floor
staff have with the specific details of each form of valve
therapy. After the postprocedure management phase, long-term, posthospital follow-up for this select group of patients
is also part of the MDT’s responsibility. Planning for and
resourcing this important phase of care is incumbent on the
MDT. Post approval registries (e.g., STS/ACC TVT Reg-
istry) (1) will be required for many of the new transcatheter
valve therapies, and, therefore, a data collection/research
unit within the MDT is another required component.
For sites with no prior trial experience in aortic trans-
catheter therapies, background experience from related pro-
cedures is important. The surgical use of ventricular assist
device support or apical conduit therapy for aortic stenosis
or left ventricular apical venting during aortic aneurysm
procedures provides excellent experience for management of
apical access for TAVR. For transcatheter procedures that
do not directly involve the surgeon as a procedure operator,
the role of the cardiac surgeon remains critically important.
The surgeon has many roles and is often a patient advocate
and/or referring physician, and is a necessary scientific study
participant in all of these device applications. The surgeon is
familiar with established standards of surgical care for
application in transcatheter therapies and is frequently in
charge of assessing high-risk patients for catheter-based
therapy as an alternative to surgery. In a valve therapy
program, neither the surgeon nor the cardiologist should be
in charge of the assessment, but rather the MDT. In all
transcatheter aortic procedures, the interventionalist and the
surgeon should be present for the critical portions of the
procedure.
Another mechanism for promoting a team approach that
involves both surgeons and cardiologists is split or shared
physician reimbursement for these procedures, which this
writing group strongly endorses. This important principle
will ensure that surgeons and cardiologists participate jointly
in performing procedures, and that each patient receives the
best and most patient-centered treatment.
The MDT should meet formally as a group on a regular
basis (aside from the usual “cath conference”) to review all
patients referred for procedures, performance of recent
procedures (to discuss both favorable and unfavorable out-
comes), and follow-up of prior procedures.
Function of the MDT
Programmatic success depends on the ability of the MDT
to function effectively in the best interest of a given patient.
To do so, the MDT must work cohesively through the
processes of patient selection, procedural planning, proce-
dural conduct, periprocedural care, and longitudinal
follow-up (1). Through each phase of this continuum, the
individual skills of the MDT members should be brought to
bear on the process.
The procedural success of transcatheter valve therapies
begins with patient selection. Given the complexity of the
decision-making process surrounding these procedures, it is
necessary that all MDT members provide objective input
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order that true informed consent be obtained, the patient
must remain at the center of the deliberations of the MDT
at all times, and must be involved in the discussions regarding
her/his therapeutic approach and goals. The patient selection
process may be initiated by use of regularly scheduled patient
selection conferences attended by all MDT members. Such
conferences are analogous to transplant patient selection com-
mittee meetings, and provide a venue in which patient-specific
data and imaging are formally presented and discussed by the
MDT. The respective expertise of each discipline represented
among MDT members may then be synthesized into a
patient-specific recommendation.
Direct patient evaluation by cardiologists and cardiac
surgeons may be accomplished jointly and, if possible,
simultaneously in a venue such as a multidisciplinary valve
rogram clinic. Not only does such a clinic provide conve-
ience for the many patients who are elderly and fragile, but it
lso provides an opportunity for cardiac surgeons and cardiol-
gists to jointly examine and evaluate complex patients.
In so doing, the expertise and judgment of both disci-
lines may be woven into a patient-specific decision. The
articipation of anesthesiologists in these clinics may also be
seful.
Following the decision that a given patient is an appro-
riate candidate for TAVR, the procedure must then be
arefully planned. Cardiac surgical teams are familiar with,
nd routinely use the concept of, “preprocedure briefings”
efore complex cardiac surgical operations. In such brief-
ngs, all team members (i.e., surgeons, anesthesiologists,
erfusionists, nurses, and technicians) discuss the intended
rocedure, including the steps of the planned procedure, the
pecific tools and equipment needed (beyond those typically
sed), the possible complications that may arise during the
ourse of the procedure, and the contingency plans that will
e implemented should the unexpected occur (1). All
embers of the team may then initiate the planned proce-
ure with a common understanding of its conduct and what
ill happen if the plan needs to change.
As integral members of the MDT, the cardiologist,
ardiovascular surgeon, and the catheterization team will
articipate actively in this preprocedure planning and MDT
riefing, which is so important for the procedural success of
ranscatheter valve therapies. During the procedure, emer-
ency situations and unexpected needs may arise. The
mmediate availability of MDT physician support in emer-
ency decision-making and therapy is essential. It is, there-
ore, important that the roles of the various specialties be
learly delineated during preprocedure planning.
Patients who undergo transcatheter valve therapies are
ften elderly and frail with multiple comorbidities. Postpro-
edure care of such patients may be difficult and entail the
anagement of multiple organ system dysfunctions. In
any cases, the initial postprocedure care should be pro-
ided in an intensive care setting. A team approach to the
are of these patients and to problem solving is importantand should include physicians skilled in critical care medi-
cine. Once in-patients are able to leave the intensive care
environment, they should be attended by a unit specializing
in the care of patients with cardiac diseases, and this unit
should be equipped with telemetry-monitored beds. Again,
a team approach is important for success. The team of
physicians, nurses, occupational and physical therapists, and
other members must have an understanding of the patho-
physiology of the particular valve condition, as well as the
nuances of care for patients who have undergone cardiac
surgery and interventional cardiology procedures.
Procedural success of transcatheter valve therapies must
be determined via longitudinal outcomes. Long-term
follow-up of these patients is an important element of the
MDT approach. Post-FDA approval registries (e.g., STS/
ACC TVT Registry) will be required for most transcatheter
valve therapies (1). Therefore, a long-term relationship
between the patient and the MDT must be established to
undertake the needed alterations in medical therapy, serial
echocardiographic imaging, and monitoring of devices.
Likewise, changes in patient functional status, heart failure
class, potential device-related complications, and other such
conditions must be carefully tracked. A valve program clinic
can provide a venue for this type of long-term follow-up.
The postmarket surveillance of transcatheter valve devices
will be an extremely important function of the MDT.
Participation in device-specific registries (e.g., STS/ACC
TVT Registry) can be challenging and requires an institu-
tional infrastructure and commitment that includes experi-
enced data managers with a background in cardiac disease,
funding, office space, and computer resources. It requires a
clinical research unit with rigorous attention to detail, and
the collection of accurate data as an integral part of the
function of the MDT.
Criteria for Establishing a
Transcatheter Valve Program and
Maintenance of Competence
An important issue in the establishment of a transcatheter
valve program is the clinical or referral base for ensuring an
adequate number of patients to provide for the viability of a
program. The requirements for the establishment of a
successful transcatheter valve program are described in
Table 1.
Once chosen for participation as TAVR programs, either
as existing programs, or as new programs, to maintain
ongoing approval for participation, sites will be monitored
to ensure that they continue to satisfy both the volume and
outcomes criteria as described in Table 2.
Unlike the experience with PCI, where data attest to the
relationship between the volume of procedures and out-
comes, there are little or no data on which to draw
conclusions as to the volume–outcome relationship for
TAVR. Therefore, these recommendations are constructed
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commitment on the part of the institution to the structural
heart disease program, and 3) use existing volume as a
surrogate for an established valve program to ensure ade-
quate patient volumes for the establishment of a sustainable
and high-quality transcatheter valve program. As experience
grows and more data become available, these recommenda-
tions will undoubtedly be refined.
Aortic Valve Replacement
Surgical aortic valve replacement is the treatment of choice
for patients with severe aortic valve disease (1). However, a
significant percentage of those patients are not offered the
procedure or simply refuse to undergo it on the basis of
excessive risks, both real and perceived (21). It is in this
context that the possibility of transcatheter aortic valve
implantation has become a reality for patients outside of the
United States. Furthermore, the cohort B results of the
PARTNER (Placement of Aortic Transcatheter) trial (non-
operable patients) would indicate that medical therapy,
including BAV, should be reserved only for patients who do
not qualify for the procedure on the basis of their anatomy
or clinical characteristics (22). Considering the reports of
successful transcatheter treatment of aortic valve stenosis
using balloons (23) and subsequent reports of poor long-
term outcomes due to early restenosis (24), the idea of
developing a transcatheter aortic valve was a logical progres-
sion. Initial animal studies (25) and subsequent human
implantations have led to the progressive development of
this technology.
Results from the PARTNER trial using the Edwards
Sapien Valve (Edwards Lifesciences, Irvine, CA), the first
randomized trial of this technology, have established its
place as a treatment of severe symptomatic aortic stenosis
(22,26). The trial consisted of two arms: cohort A (n 
699), the high risk surgical group, which randomized
patients to surgical aortic valve replacement or TAVR, and
cohort B (n  358), the nonsurgical group randomized to
medical therapy, which could include valvuloplasty or
TAVR. Results from the noninferiority cohort A group
showed a 1 year all-cause mortality of 26.8% in the surgical
arm and 24.2% in the TAVR arm, a hazard ratio (HR) (95%
CI) of 0.93 (0.7, 1.22), which met the noninferiority
endpoint, p  0.001 (for a noninferiority margin of 7.5
percentage points). There were differences in outcomes
between the groups, the most worrisome being a higher
incidence of stroke or transient ischemic attack (TIA) at 30
days and at 1 year in the TAVR arm (at 30 days: 5.5% versus
2.4%, p  0.04 and at 1 year: 8.3% versus 4.3%, p  0.04).
The need for a new permanent pacemaker was not different
between the groups, 5.7% in the surgical arm versus 5.0% in
the TAVR arm, p  0.68. In cohort B, TAVR was found
to be superior to medical therapy with an all-cause mortality
at 1 year of 50.7% in the medical arm versus 30.7% in theTAVR arm, HR (95% CI) 0.54 (0.58, 0.78, p  0.001).
These findings suggest that it is necessary to treat five
patients to prevent one death (27). PARTNER II, which
uses a new, lower profile delivery system, is in the early
stages of patient recruitment. To date, there are no random-
ized data regarding the CoreValve prosthesis (Medtronic,
Minneapolis, MN) but it has received the CE mark in
Europe, as has the Sapien valve.
Registry data appear to show favorable hemodynamic
outcomes and acceptable mortality (28,29). In this large
multicenter registry consisting of 14 centers reporting on
663 consecutive patients (29), procedure success was 98%
with a procedural mortality of 0.9%. Thirty-day mortality
was 5.4% and 15.0% at 1 year. Stroke during the procedure
and at 1 year was 1.2% and 2.5%, respectively. The
requirement for a permanent pacemaker was 19.1% at 1
year, a rate similar to other registries reporting outcomes
using this valve. Independent predictors of mortality at 30
days included conversion to open heart surgery (odds ratio
[OR] 38.68), cardiac tamponade (OR 10.97), major access
site complications (OR 8.47), left ventricular ejection frac-
tion 40% (OR 3.51), prior balloon valvuloplasty (OR
2.87), and diabetes mellitus (OR 2.66). Predictors of late
mortality (30 days to 1 year) included prior stroke (HR
5.47), post procedural paravalvular leak is 2 (HR 3.79),
prior acute pulmonary edema (HR 2.70), and chronic
kidney disease (HR 2.53). The CoreValve US Pivotal Trial
is currently randomizing patients in a similar fashion to the
PARTNER trial and should yield additional important data
on this valve.
Research/Registry
FDA clearance of a novel valve repair or replacement
prosthesis does not guarantee that the device will continue
to demonstrate long-term efficacy equal to currently avail-
able options, or that its application will be limited to the
initially approved patient subsets. Postmarket studies orga-
nized through individual institutions or multicenter study
groups and registries managed by industry and professional
societies are essential for ensuring continued short-term
safety, and for determining long-term efficacy. Only with
such data can we consider application of new valve prosthe-
ses to a wider patient population outside the boundaries of
the study groups examined during FDA trials. Centers that
incorporate transcatheter-based therapies into their practice
absolutely must participate in a cardiac surgery or cardiology
national database such as the STS National Database,
Northern New England Cardiac Disease Study Group,
American College of Cardiology’s National Cardiovascular
Data Registry, or an equivalent database (30–32). These
databases facilitate continued analysis of early outcomes on
a national level; however, most do not permit analysis of results
beyond the 30-day window, mandating the development of
implant registries with patient consent, permitting late
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reinterventions. These valve repair and replacement procedures
should be registered in databases capable of providing both
acute outcome and long-term follow-up data.
Early postprocedure morbidity and mortality analyses,
while important for initial and continued implant safety
assessment, are not sufficient to evaluate the efficacy of valve
repair or replacement prostheses. Studies on long-term
follow-up survival and, more importantly, structural valve
degeneration, and the need for reintervention, are essential.
Recent attempts to link the STS National Database to an
administrative survival database (Social Security Death
Master File) or to CMS Medicare data have been promis-
ing; however, survival data alone will not be sufficient for
transcatheter valve registries (e.g., STS/ACC TVT Registry
[33]). Risk adjustment using only administrative data is
challenging and may be more important in this highly
complex patient population. Transcatheter valve registries
must incorporate late assessment of structural valve degen-
eration and the need for late reoperation or reintervention.
Long-term function data is also essential before application
of new valve repair or replacement technology can be
considered for lower risk and younger patients. Clinicians
must be careful not to extrapolate outcomes generated
during FDA trials to patients that do not reasonably
approximate the trial study populations. At present, it is not
acceptable for clinicians to apply “off label” transcatheter
techniques to patients who are otherwise excellent candi-
dates for conventional valve repair or replacement outside
the confines of a randomized, controlled trial or, at a
minimum, multicenter, national, prospective studies.
The potential negative impact of a valve prosthesis recall,
in regards to the increased risk associated with reoperative
surgery for a permanent implant, far outweighs that associ-
ated with the removal of a pharmacologic agent from the
market (34). Thus, the allocation of adequate funding to
allow complete follow-up studies is essential, including
financial support from industry, the FDA, National Insti-
tutes of Health, CMS, and professional societies, with
scientific oversight distanced from industry and potential
conflicts of interest. Postmarket surveillance governed solely
by industry self-regulation can be of dubious value. In a
2005 editorial, Eugene Blackstone cautioned, “Industry has
not developed a viable mechanism for dealing with ‘bad
news,’ the disclosure of which often leads to the demise of
the company” (35). The Interagency Registry for Mechani-
cally Assisted Circulatory Support exemplifies a potentially
efficient model that could be emulated by professional societies
for monitoring transcatheter inventions during the next de-
cade, during which durability data will be generated (36).
Transcatheter valve repair or replacement devices are
unique in that an understanding not only of early risk, but
also of long-term durability, is essential for determining the
appropriate patient subgroups for these therapies. In our
opinion, it is the responsibility of professional societies to
ensure adequate long-term data monitoring and provideoversight and guidance to industry on the expectations for
continued monitoring beyond the FDA approval phase of
device development and implementation. Individual centers
are also responsible for critically evaluating their own
experience, through local and regional quality improvement
initiatives, and for participating in national databases and
registries (e.g., STS/ACC TVT Registry) that facilitate
continued safety and efficacy in the assessment of novel, and,
as yet, unproven, therapeutic options. Components of a
national/international registry should include preoperative
risk factors and valve assessment, intraoperative details, early
postoperative morbidity, and late follow-up including survival,
need for reintervention, functional class, device-related com-
plications and late assessment of valve performance. It is
inappropriate to perform these novel and innovative procedures
without the institutional infrastructure to ensure adequate early
data collection and later follow-up.
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